{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:42:58Z","timestamp":1794490978946,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.eururo.2024.01.007","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T20:54:10Z","timestamp":1709067250000},"page":"574-585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy"],"prefix":"10.1016","volume":"85","author":[{"given":"Jonathan E.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Vulsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Masumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Meran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Skaltsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Matsangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Hepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.01.007_b0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: Challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2024.01.007_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fphar.2013.00003","article-title":"Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches","volume":"4","author":"Bambury","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eururo.2024.01.007_b0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41571-018-0026-y","article-title":"Treatment resistance in urothelial carcinoma: an evolutionary perspective","volume":"15","author":"Vlachostergios","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2024.01.007_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.705294","article-title":"Elucidation of novel molecular targets for therapeutic strategies in urothelial carcinoma: a literature review","volume":"11","author":"Nelson","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.01.007_b0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11764-016-0580-1","article-title":"Patient-reported outcome measures of the impact of cancer on patients\u2019 everyday lives: a systematic review","volume":"11","author":"Catt","year":"2017","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.eururo.2024.01.007_b0030","unstructured":"United States Food & Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/media\/77832\/download."},{"key":"10.1016\/j.eururo.2024.01.007_b0035","unstructured":"United States Food & Drug Administration. Core patient-reported outcomes in cancer clinical trials: guidance for industry. https:\/\/www.fda.gov\/media\/149994\/download."},{"key":"10.1016\/j.eururo.2024.01.007_b0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.eururo.2024.01.007_b0045","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from keynote-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.01.007_b0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12894-020-00752-w","article-title":"Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (range)","volume":"20","author":"Necchi","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2024.01.007_b0055","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/jcm10091852","article-title":"Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo- or immunotherapy: a real-life experience","volume":"10","author":"Taarnhoj","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.eururo.2024.01.007_b0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/cncr.32532","article-title":"Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced\/metastatic urothelial carcinoma treated with durvalumab in phase 1\/2 dose-escalation study 1108","volume":"126","author":"O\u2019Donnell","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.01.007_b0065","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2024.01.007_b0070","unstructured":"Astellas Pharma US. Padcev\u00ae (enfortumab vedotin-ejfv) for injection: prescribing information. https:\/\/astellas.us\/docs\/PADCEV_label.pdf."},{"key":"10.1016\/j.eururo.2024.01.007_b0075","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.01.007_b0080","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.01.007_b0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.01.007_b0090","unstructured":"EuroQol Office. EQ-5D-5L. Updated April 18, 2017. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/."},{"key":"10.1016\/j.eururo.2024.01.007_b0095","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.01.007_b0100","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/cncr.11413","article-title":"Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group","volume":"97","author":"Dreicer","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.01.007_b0105","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: a systematic review of the past 40 years","volume":"18","author":"van den Beuken-van Everdingen","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.01.007_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/BLC-211518","article-title":"Qualitative analysis of pain in patients with locally advanced or metastatic urothelial carcinoma","volume":"8","author":"Martin","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2024.01.007_b0115","first-page":"787","article-title":"Pathophysiology and clinical characteristics of pain in most common locations in cancer patients","volume":"67","author":"Leppert","year":"2016","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.eururo.2024.01.007_b0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jpainsymman.2006.05.012","article-title":"The prevalence of concern about weight loss and change in eating habits in people with advanced cancer","volume":"32","author":"Hopkinson","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.eururo.2024.01.007_b0125","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1200\/JCO.2005.06.866","article-title":"Prognostic factors in advanced cancer patients: evidence-based clinical recommendations\u2014a study by the steering committee of the European Association for Palliative Care","volume":"23","author":"Maltoni","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.01.007_b0130","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jval.2020.12.015","article-title":"Does knowledge of treatment assignment affect patient report of symptoms, function, and health status? An evaluation using multiple myeloma trials","volume":"24","author":"Roydhouse","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.eururo.2024.01.007_b0135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11136-021-02945-8","article-title":"Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review","volume":"31","author":"Anota","year":"2022","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2024.01.007_b0140","unstructured":"Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values 2008. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf."},{"key":"10.1016\/j.eururo.2024.01.007_b0145","doi-asserted-by":"crossref","first-page":"e110216","DOI":"10.1371\/journal.pone.0110216","article-title":"Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers","volume":"9","author":"Calvert","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2024.01.007_b0150","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fonc.2019.00783","article-title":"The role of response-shift in studies assessing quality of life outcomes among cancer patients: a systematic review","volume":"9","author":"Ilie","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.01.007_b0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12955-020-01663-y","article-title":"Response shift in health-related quality of life measures in the presence of formative indicators","volume":"19","author":"Testa","year":"2021","journal-title":"Health Qual Life Outcomes"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:30:07Z","timestamp":1762288207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0302283824000083"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.01.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}